Table 3 Multispecific NK cell engagers in clinical trials (all stages), as of July 2023
From: Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies
Drug name | Format | Specificity | Indication | Clinical trial | Phase | Sponsor |
|---|---|---|---|---|---|---|
AFM13 | TandAb | CD30/CD16a | HL, NHL | NCT04074746 | 1/2 | Affimed |
AFM28 | IgG-like ROCK | CD123/CD16a | AML | NCT05817058 | 1 | Affimed |
LAVA-051 | Gammabody | CD1d/NKT TCR | CLL, MM, AML | NCT04887259 | 1/2 | Lava Therapeutics |
IPH6101/SAR443579 | ANKET | CD123/CD16/NKp46 | AML, MDS | NCT05086315 | 1/2 | Sanofi |
IPH6401/SAR445514 | ANKET | BCMA/CD16/NKp46 | R/R MM | NCT05839626 | 1/2 | Sanofi |
CC-92328/DF3001 | TriNKET | BCMA/CD16/NKG2D | R/R MM | NCT04975399 | 1 | Celgene (BMS) |
CC-96191/DF2001 | TriNKET | CD33/CD16/KNG2D | R/R AML | NCT04789655 | 1 | Celgene (BMS) |